2013

U.S. Department of Justice reaches a settlement of $3 billion with GlaxoSmithKline for various “misdeeds” regarding the anti-nausea drug Zofran, including promoting it to pregnant women with morning sickness, for which it was not approved, illegal efforts to keep competing nausea drugs off the market, and pay=for-delay deals to keep generic Zofran and much cheaper anti-nausea drugs (e.g., generic Compazine) off the market (for which it was sued by South Korea) (Rosenthal, 121).